403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Briacell Therapeutics Corp.
(MENAFN- Baystreet) 11:46 AM EST - BriaCell Therapeutics Corp. : Announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune checkpoint inhibitor. BriaCell Therapeutics Corp.
shares T are trading up $0.03 at $2.83.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment